Merck in Pact for Chinese Obesity Drug in Nearly $2 Billion Deal
Merck & Co. snagged a potential drug in the burgeoning market for obesity medications in a deal worth as much as $2 billion.
Merck reaches weight-loss drug deal worth up to $2 billion with China-based Hansoh
Merck announced a weight loss drug deal Wednesday with China-based Hansoh worth up to $2 billion for the pill code-named ...
Merck calls quits on two immunotherapies for cancer
The company is scrapping two drugs aimed at targets called TIGIT and LAG-3, both of which were in the middle of Phase 3 ...
Merck Enters Into Exclusive Global License Agreement With Hansoh Pharma For HS-10535
(RTTNews) - Merck & Co., Inc. (MRK), Wednesday announced that the company has entered into an exclusive global license deal with China-based Hansoh Pharma to develop, manufacture and commercialize ...
Merck discontinues development of 2 experimental cancer drugs after trial failures
Merck said on Monday it has discontinued the development of two experimental cancer drugs after their failure in several ...
Merck targets 2025 RSV season with antibody now under FDA review
An FDA approval of Merck’s drug clesrovimab by June would give physicians another option for protecting newborns from ...
Merck & Co. Inc. stock remains steady Tuesday, still outperforms market
Shares of Merck & Co. Inc. MRK were unchanged Tuesday, on what proved to be an all-around dismal trading session for the ...
Merck: Buy Opportunity Backed By Growth
Merck's strong financial performance in oncology and vaccines drove a 9% sales increase earlier in Q1 of 2024. See why I rate ...